Release Summary

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) today announced the publication of preclinical data on CAT-5571, a novel activator of autophagy and potential oral treatment for cystic fibrosis (CF).

Catabasis Pharmaceuticals, Inc.